中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 12
Dec.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(12): 2932-2941

Research advances in signaling pathways associated with potential anti-liver fibrosis drugs and targets

DOI: 10.3969/j.issn.1001-5256.2023.12.027
  • 1.

    Graduate School of Hebei Medical University，Shijiazhuang 050017，China

  • 2.

    Department of Pharmacy，Hebei General Hospital，Shijiazhuang 050057，China

Research funding:

Project of Health Commission of Hebei Province (20210037)

More Information
  • Corresponding author: DONG Zhanjun， 13313213656@126.com （ORCID： 0000-0001-5349-4970）
  • Received Date: 2023-03-13
  • Accepted Date: 2023-05-09
  • Published Date: 2023-12-12
    Abstract
  • Liver fibrosis is a key step in the progression of chronic liver diseases to liver cirrhosis and even liver cancer. In recent years， a large number of studies have shown the necessity of intervening in the process of liver fibrosis， and various anti-liver fibrosis drugs and active ingredients have been discovered. Non-coding RNAs also play an important role in the process of liver fibrosis， and searching for upstream non-coding RNAs that can regulate signaling pathways can provide new insights for anti-liver fibrosis treatment. This article introduces the process of liver fibrosis mediated by the TGF-β， Wnt/β-catenin， PI3K/Akt/mTOR， NF-κβ， Hippo， and MAPK signaling pathways， lists the latest anti-liver fibrosis drugs or active components in each signaling pathway， and summarizes the research advances in anti-liver fibrosis targets and drugs mediated by related non-coding RNAs， so as to provide new research ideas and treatment methods for anti-liver fibrosis treatment.

     

    • FullText(HTML)
  • loading
    • References(55)
  • [1]
    WANG FS, FAN JG, ZHANG Z, et al. The global burden of liver disease: The major impact of China[J]. Hepatology, 2014, 60( 6): 2099- 2108. DOI: 10.1002/hep.27406.
    [2]
    OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. Hepatol Int, 2017, 11( 4): 317- 370. DOI: 10.1007/s12072-017-9799-9.
    [3]
    KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 3): 151- 166. DOI: 10.1038/s41575-020-00372-7.
    [4]
    DEWIDAR B, MEYER C, DOOLEY S, et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019[J]. Cells, 2019, 8( 11): 1419. DOI: 10.3390/cells8111419.
    [5]
    CHEN L, YANG T, LU DW, et al. Central role of dysregulation of TGF-β/SMAD in CKD progression and potential targets of its treatment[J]. Biomed Pharmacother, 2018, 101: 670- 681. DOI: 10.1016/j.biopha.2018.02.090.
    [6]
    WALTON KL, JOHNSON KE, HARRISON CA. Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis[J]. Front Pharmacol, 2017, 8: 461. DOI: 10.3389/fphar.2017.00461.
    [7]
    TARIQ S, KOLOKO BL, MALIK A, et al. Tectona grandis leaf extract ameliorates hepatic fibrosis: Modulation of TGF-β/SMAD signaling pathway and upregulating MMP3/TIMP1 ratio[J]. J Ethnopharmacol, 2021, 272: 113938. DOI: 10.1016/j.jep.2021.113938.
    [8]
    ELRAZIK NAA, EL-MESERY M, EL-SHISHTAWY MM. Sesamol protects against liver fibrosis induced in rats by modulating lysophosphatidic acid receptor expression and TGF-β/SMAD3 signaling pathway[J]. Naunyn Schmiedebergs Arch Pharmacol, 2022, 395( 8): 1003- 1016. DOI: 10.1007/s00210-022-02259-7.
    [9]
    SUN YM, LIU BY, XIE JP, et al. Aspirin attenuates liver fibrosis by suppressing TGF‑β1/smad signaling[J]. Mol Med Rep, 2022, 25( 5): 181. DOI: 10.3892/mmr.2022.12697.
    [10]
    SHU GW, DAI CX, YUSUF A, et al. Limonin relieves TGF-β-induced hepatocyte EMT and hepatic stellate cell activation in vitro and CCl4-induced liver fibrosis in mice via upregulating SMAD7 and subsequent suppression of TGF-β/SMAD cascade[J]. J Nutr Biochem, 2022, 107: 109039. DOI: 10.1016/j.jnutbio.2022.109039.
    [11]
    ZHANG YE. Non-smad signaling pathways of the TGF-β family[J]. Cold Spring Harb Perspect Biol, 2017, 9( 2): a022129. DOI: 10.1101/cshperspect.a022129.
    [12]
    VARGAS-POZADA EE, RAMOS-TOVAR E, ACERO-HERNÁNDEZ C, et al. Caffeine mitigates experimental nonalcoholic steatohepatitis and the progression of thioacetamide-induced liver fibrosis by blocking the MAPK and TGF-β/SMAD3 signaling pathways[J]. Ann Hepatol, 2022, 27( 2): 100671. DOI: 10.1016/j.aohep.2022.100671.
    [13]
    ABDEL-RAHMAN RF, FAYED HM, ASAAD GF, et al. The involvement of TGF-β1/FAK/α-SMA pathway in the antifibrotic impact of rice bran oil on thioacetamide-induced liver fibrosis in rats[J]. PLoS One, 2021, 16( 12): e0260130. DOI: 10.1371/journal.pone.0260130.
    [14]
    WANG HL, CHE JY, CUI K, et al. Schisantherin A ameliorates liver fibrosis through TGF-β1mediated activation of TAK1/MAPK and NF-κB pathways in vitro and in vivo[J]. Phytomedicine, 2021, 88: 153609. DOI: 10.1016/j.phymed.2021.153609.
    [15]
    YAN YF, ZENG JF, XING LH, et al. Extra- and intra-cellular mechanisms of hepatic stellate cell activation[J]. Biomedicines, 2021, 9( 8): 1014. DOI: 10.3390/biomedicines9081014.
    [16]
    EL-FADALY AA, AFIFI NA, EL-ERAKY W, et al. Fisetin alleviates thioacetamide-induced hepatic fibrosis in rats by inhibiting Wnt/β-catenin signaling pathway[J]. Immunopharmacol Immunotoxicol, 2022, 44( 3): 355- 366. DOI: 10.1080/08923973.2022.2047198.
    [17]
    LEE IH, IM E, LEE HJ, et al. Apoptotic and antihepatofibrotic effect of honokiol via activation of GSK3β and suppression of Wnt/β-catenin pathway in hepatic stellate cells[J]. Phytother Res, 2021, 35( 1): 452- 462. DOI: 10.1002/ptr.6824.
    [18]
    PORTA C, PAGLINO C, MOSCA A. Targeting PI3K/akt/mTOR signaling in cancer[J]. Front Oncol, 2014, 4: 64. DOI: 10.3389/fonc.2014.00064.
    [19]
    FEDELE CG, OOMS LM, HO M, et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers[J]. Proc Natl Acad Sci USA, 2010, 107( 51): 22231- 22236. DOI: 10.1073/pnas.1015245107.
    [20]
    XIU AY, DING Q, LI Z, et al. Doxazosin attenuates liver fibrosis by inhibiting autophagy in hepatic stellate cells via activation of the PI3K/Akt/mTOR signaling pathway[J]. Drug Des Devel Ther, 2021, 15: 3643- 3659. DOI: 10.2147/DDDT.S317701.
    [21]
    LEE SW, KIM SM, HUR W, et al. Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway[J]. PLoS One, 2021, 16( 12): e0261067. DOI: 10.1371/journal.pone.0261067.
    [22]
    LIN X, WEI YY, LI Y, et al. Tormentic acid ameliorates hepatic fibrosis in vivo by inhibiting glycerophospholipids metabolism and PI3K/Akt/mTOR and NF-κB pathways: Based on transcriptomics and metabolomics[J]. Front Pharmacol, 2022, 13: 801982. DOI: 10.3389/fphar.2022.801982.
    [23]
    LUEDDE T, SCHWABE RF. NF-κB in the liver: Linking injury, fibrosis and hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2011, 8( 2): 108- 118. DOI: 10.1038/nrgastro.2010.213.
    [24]
    TANIGUCHI K, KARIN M. NF-κB, inflammation, immunity and cancer: Coming of age[J]. Nat Rev Immunol, 2018, 18( 5): 309- 324. DOI: 10.1038/nri.2017.142.
    [25]
    ZHAO YC, LIU XL, DING CB, et al. Dihydromyricetin reverses thioacetamide-induced liver fibrosis through inhibiting NF-κB-mediated inflammation and TGF-β1-regulated of PI3K/Akt signaling pathway[J]. Front Pharmacol, 2021, 12: 783886. DOI: 10.3389/fphar.2021.783886.
    [26]
    de SOUZA BASSO B, HAUTE GV, ORTEGA-RIBERA M, et al. Methoxyeugenol deactivates hepatic stellate cells and attenuates liver fibrosis and inflammation through a PPAR-ɣ and NF-kB mechanism[J]. J Ethnopharmacol, 2021, 280: 114433. DOI: 10.1016/j.jep.2021.114433.
    [27]
    RAJ D, SHARMA V, UPADHYAYA A, et al. Swertia purpurascens Wall ethanolic extract mitigates hepatic fibrosis and restores hepatic hepcidin levels via inhibition of TGFβ/SMAD/NFκB signaling in rats[J]. J Ethnopharmacol, 2022, 284: 114741. DOI: 10.1016/j.jep.2021.114741.
    [28]
    SHARAWY MH, EL-KASHEF DH, SHAABAN AA, et al. Anti-fibrotic activity of sitagliptin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation/NF-κB inhibition[J]. Int Immunopharmacol, 2021, 100: 108088. DOI: 10.1016/j.intimp.2021.108088.
    [29]
    NOGUCHI S, SAITO A, NAGASE T. YAP/TAZ signaling as a molecular link between fibrosis and cancer[J]. Int J Mol Sci, 2018, 19( 11): 3674. DOI: 10.3390/ijms19113674.
    [30]
    LI CX, ZHANG RR, ZHAN YT, et al. Resveratrol inhibits hepatic stellate cell activation via the hippo pathway[J]. Mediators Inflamm, 2021, 2021: 3399357. DOI: 10.1155/2021/3399357.
    [31]
    MA TT, CHENG HL, LI TX, et al. N-Acetyl-l-tryptophan inhibits CCl4-induced hepatic fibrogenesis via regulating TGF-β1/SMAD and Hippo/YAP1 signal[J]. Bioorg Chem, 2022, 126: 105899. DOI: 10.1016/j.bioorg.2022.105899.
    [32]
    KIM EK, CHOI EJ. Compromised MAPK signaling in human diseases: An update[J]. Arch Toxicol, 2015, 89( 6): 867- 882. DOI: 10.1007/s00204-015-1472-2.
    [33]
    CAI SY, WU LJ, YUAN SY, et al. Carvacrol alleviates liver fibrosis by inhibiting TRPM7 and modulating the MAPK signaling pathway[J]. Eur J Pharmacol, 2021, 898: 173982. DOI: 10.1016/j.ejphar.2021.173982.
    [34]
    KATAOKA S, UMEMURA A, OKUDA K, et al. Honokiol acts as a potent anti-fibrotic agent in the liver through inhibition of TGF-β1/SMAD signaling and autophagy in hepatic stellate cells[J]. Int J Mol Sci, 2021, 22( 24): 13354. DOI: 10.3390/ijms222413354.
    [35]
    ZHANG TP, HU JJ, WANG XM, et al. microRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway[J]. J Hepatol, 2019, 70( 1): 87- 96. DOI: 10.1016/j.jhep.2018.08.026.
    [36]
    HE C, SHU B, ZHOU YX, et al. The miR-139-5p/peripheral myelin protein 22 axis modulates TGF-β-induced hepatic stellate cell activation and CCl4-induced hepatic fibrosis in mice[J]. Life Sci, 2021, 276: 119294. DOI: 10.1016/j.lfs.2021.119294.
    [37]
    YANG X, SHU B, ZHOU YX, et al. Ppic modulates CCl4-induced liver fibrosis and TGF-β-caused mouse hepatic stellate cell activation and regulated by miR-137-3p[J]. Toxicol Lett, 2021, 350: 52- 61. DOI: 10.1016/j.toxlet.2021.06.021.
    [38]
    ZHOU QY, YANG HM, LIU JX, et al. microRNA-497 induced by Clonorchis sinensis enhances the TGF-β/SMAD signaling pathway to promote hepatic fibrosis by targeting SMAD7[J]. Parasit Vectors, 2021, 14( 1): 472. DOI: 10.1186/s13071-021-04972-3.
    [39]
    GAO HB, WANG XM, MA HX, et al. LncRNA CCAT2, involving miR-34a/TGF-β1/SMAD4 signaling, regulate hepatic stellate cells proliferation[J]. Sci Rep, 2022, 12( 1): 21199. DOI: 10.1038/s41598-022-25738-6.
    [40]
    WANG N, LI XJ, ZHONG ZY, et al. 3D hESC exosomes enriched with miR-6766-3p ameliorates liver fibrosis by attenuating activated stellate cells through targeting the TGFβRII-SMADS pathway[J]. J Nanobiotechnology, 2021, 19( 1): 437. DOI: 10.1186/s12951-021-01138-2.
    [41]
    WANG H, WANG Z, WANG YR, et al. miRNA-130b-5p promotes hepatic stellate cell activation and the development of liver fibrosis by suppressing SIRT4 expression[J]. J Cell Mol Med, 2021, 25( 15): 7381- 7394. DOI: 10.1111/jcmm.16766.
    [42]
    YANG JF, XU CQ, WU MM, et al. microRNA-124 inhibits hepatic stellate cells inflammatory cytokines secretion by targeting IQGAP1 through NF-κB pathway[J]. Int Immunopharmacol, 2021, 95: 107520. DOI: 10.1016/j.intimp.2021.107520.
    [43]
    ZHU YZ, HU YB, CHENG XY, et al. Elevated miR-129-5p attenuates hepatic fibrosis through the NF-κB signaling pathway via PEG3 in a carbon CCl4 rat model[J]. J Mol Histol, 2021, 52( 3): 491- 501. DOI: 10.1007/s10735-020-09949-7.
    [44]
    YAO J, LIN CH, JIANG JJ, et al. lncRNA-HEIM facilitated liver fibrosis by up-regulating TGF-β expression in long-term outcome of chronic hepatitis B[J]. Front Immunol, 2021, 12: 666370. DOI: 10.3389/fimmu.2021.666370.
    [45]
    LI YZ, LIU PX, WEI FP. Long non‑coding RNA MBI‑52 inhibits the development of liver fibrosis by regulating the microRNA‑466g/SMAD4 signaling pathway[J]. Mol Med Rep, 2022, 25( 1): 33. DOI: 10.3892/mmr.2021.12549.
    [46]
    ZHANG K, HAN XH, ZHANG Z, et al. The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch pathways[J]. Nat Commun, 2017, 8( 1): 144. DOI: 10.1038/s41467-017-00204-4.
    [47]
    LIAO JM, ZHANG Z, YUAN Q, et al. The mouse Anxa6/miR-9-5p/Anxa2 axis modulates TGF-β1-induced mouse hepatic stellate cell(mHSC) activation and CCl4-caused liver fibrosis[J]. Toxicol Lett, 2022, 362: 38- 49. DOI: 10.1016/j.toxlet.2022.04.004.
    [48]
    WANG Y, XIAO X, WANG XB, et al. Identification of differentially expressed long noncoding RNAs and pathways in liver tissues from rats with hepatic fibrosis[J]. PLoS One, 2021, 16( 10): e0258194. DOI: 10.1371/journal.pone.0258194.
    [49]
    ZHAN YT, TAO QQ, MENG QS, et al. LncRNA-MIAT activates hepatic stellate cells via regulating Hippo pathway and epithelial-to-mesenchymal transition[J]. Commun Biol, 2023, 6( 1): 285. DOI: 10.1038/s42003-023-04670-z.
    [50]
    ZHANG K, ZHANG MX, YAO QB, et al. The hepatocyte-specifically expressed lnc-HSER alleviates hepatic fibrosis by inhibiting hepatocyte apoptosis and epithelial-mesenchymal transition[J]. Theranostics, 2019, 9( 25): 7566- 7582. DOI: 10.7150/thno.36942.
    [51]
    ZHU S, CHEN X, WANG JN, et al. Circular RNA circUbe2k promotes hepatic fibrosis via sponging miR-149-5p/TGF-β2 axis[J]. FASEB J, 2021, 35( 6): e21622. DOI: 10.1096/fj.202002738R.
    [52]
    MA L, WEI JF, ZENG YL, et al. Mesenchymal stem cell-originated exosomal circDIDO1 suppresses hepatic stellate cell activation by miR-141-3p/PTEN/AKT pathway in human liver fibrosis[J]. Drug Deliv, 2022, 29( 1): 440- 453. DOI: 10.1080/10717544.2022.2030428.
    [53]
    QIU JL, ZHANG GF, CHAI YN, et al. Ligustrazine attenuates liver fibrosis by targeting miR-145 mediated transforming growth factor-β/smad signaling in an animal model of biliary atresia[J]. J Pharmacol Exp Ther, 2022, 381( 3): 257- 265. DOI: 10.1124/jpet.121.001020.
    [54]
    ZAAFAN MA, ABDELHAMID AM. Dasatinib ameliorates thioacetamide-induced liver fibrosis: Modulation of miR-378 and miR-17 and their linked Wnt/β-catenin and TGF-β/smads pathways[J]. J Enzyme Inhib Med Chem, 2022, 37( 1): 118- 124. DOI: 10.1080/14756366.2021.1995379.
    [55]
    LI XH, LI HL, ZHANG SS, et al. Protective effect of Idelalisib on carbon tetrachloride-induced liver fibrosis via microRNA-124-3P/phosphatidylinositol-3-hydroxykinase signalling pathway[J]. J Cell Mol Med, 2021, 25( 24): 11185- 11197. DOI: 10.1111/jcmm.17039.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (193) PDF downloads(41) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return